Breast cancer staging for patients with "low-risk" disease: Are they all the same? - PubMed
7 days ago
- #staging
- #breast cancer
- #oncotype
- Breast cancer staging incorporates both anatomic and biologic factors.
- A low Oncotype Recurrence Score (RS < 11) is linked to favorable survival but may not justify downstaging to pathologic prognostic stage (PPS) IA alone.
- Study analyzed 231,031 patients (2010-2018) with hormone receptor-positive, HER2-negative, pT1-3/pN0-1/M0 breast cancer.
- Patients with RS < 11 mostly (94.2%) had PPS IA, but overall survival (OS) declined with higher stages.
- Adjusted analyses showed worse OS for higher stages even within the RS < 11 group.
- In the RS 11-17 group, 90.8% were PPS IA, but 5-year OS varied by stage.
- Prognostic stage significantly influences survival among patients with low RS.
- RS < 11 alone should not automatically downstage patients to PPS IA; anatomic and other factors remain important for prognosis.